Home
Search
thewest.com.au
BusinessChevron Right Icon

Biotech

Rohan Hockings has resigned as chief of WA biotech PYC Therapeutics.

BiotechCommentsPremiumAlan Tribe takes over as interim PYC Therapeutics boss

PYC Therapeutics has announced chair Alan Tribe will assume the role of interim managing director following Rohan Hockings’ resignation from the top job.

Cheyanne Enciso

Orthocell chair John Van Der Wielen and chief executive officer Paul Anderson at the biotech’s headquarters in Murdoch.

BiotechCommentsPremiumOrthocell’s Remplir used in nerve-sparing prostate surgery

Australian urologists are now using Orthocell’s flagship nerve repair product during prostate cancer surgery in what the WA biotech says has potential to reduce the risks of erectile dysfunction.

Cheyanne Enciso

CSL will make an upfront payment of $US117 million for the right to buy privately held VarmX BV. (James Ross/AAP PHOTOS)

HealthPremiumCSL in $757m deal with pioneering Dutch biotech

CSL is paying to partner with a Dutch company developing an emergency treatment for patients on blood thinners who experience uncontrolled bleeding.

Derek Rose

CSL is Australia’s third-biggest company by market capitalisation at over $120 billion.

BiotechCommentsBiotech giant CSL to cut 3000 jobs, spin off flu arm

Biotech giant CSL is set to axe almost 3000 jobs globally as it announces a major restructure and savings drive that will see its flu vaccine arm spun off into a separately listed company.

Cheyanne Enciso

Emyria executive director Michael Winlo.

BiotechCommentsPremiumEmyria expands MDMA national reach with new Brisbane clinic

WA biotech Emyria will deliver its MDMA-based therapy aimed at treating post-traumatic stress disorder to Brisbane patients after inking a deal with a national mental health hospital operator.

Cheyanne Enciso

Emyria executive director Michael Winlo.

BiotechCommentsPremiumEmyria in MDMA national rollout bid following landmark deal

WA biotech Emyria says it’s in talks with other major Australian insurers to fund the use of MDMA-based therapy to treat post-traumatic stress disorder following a landmark deal with Medibank.

Cheyanne Enciso

Kim Beazley joined the board of Perth biotech Orthocell last year.

BiotechCommentsPremiumHealth issues force Kim Beazley’s exit from Orthocell

Former WA governor and US ambassador Kim Beazley will step down from the board of Perth regenerative medicine company Orthocell due to health reasons.

Cheyanne Enciso

CSL is Australia’s third-biggest company by market capitalisation at over $120 billion.

BiotechCommentsTrump pharma tariff to have ‘limited’ impact on biotech: UBS

Investment bank UBS expects Donald Trump’s tariff threat on pharmaceuticals to have ‘limited’ impact on biotech giant CSL, especially if plasma products are excluded.

Cheyanne Enciso

Medicines and pharmaceutical products were the third-largest good exported to the US in 2024, with the trade worth more than $2 billion that year.

BiotechCommentsPremiumTrump’s pharma tariff could send local biotechs offshore

The peak body for Australia’s life sciences industry has flagged concerns Donald Trump’s pharmaceutical tariff threat could force more local biotechs and medical technology firms to move operations overseas.

Cheyanne Enciso

Orthocell chair John Van Der Wielen with chief executive officer Paul Anderson.

BiotechCommentsPremiumTrump’s pharma tariff threat a ‘cage-rattling exercise’

The boss of WA regenerative medicine company Orthocell has labelled Donald Trump’s latest tariff threat on pharmaceuticals as a ‘cage-rattling exercise’ to try elicit panic from the Australian Government.

Cheyanne Enciso

Orthocell chair John Van Der Wielen with chief executive officer Paul Anderson.

BiotechCommentsPremiumOrthocell shares higher as WA biotech posts record revenue

WA biotech Orthocell has posted record revenue for the June quarter as sales for its nerve repair technology surge in Australia, ahead of an expected ramp up in US.

Cheyanne Enciso

Orthocell chief executive Paul Anderson and chair John Van Der Wielen.

BiotechCommentsPremiumOrthocell’s nerve repair tech marks first surgical use in US

WA regenerative medicine firm Orthocell says it has marked another commercialisation milestone with the first successful surgical use of its nerve repair product in the US.

Cheyanne Enciso

Argenica Therapeutics boss Liz Dallimore.

BiotechCommentsPremiumWA’s Argenica wins $1m funding for life-saving stroke drug

The Federal Government is pumping $1 million into WA biotech Argenica Therapeutics to advance global clinical trials for its potentially life-saving stroke drug.

Cheyanne Enciso

Emyria executive director Michael Winlo.

BiotechCommentsPremiumEmyria wins major insurer backing for MDMA-assisted therapy

Australia’s biggest health insurer is backing the use of MDMA-based therapy to treat post-traumatic stress disorder in a landmark deal signed with a WA-based biotech.

Cheyanne Enciso

Orthocell chair John Van Der Wielen and chief Paul Anderson at its HQ in Murdoch.

BiotechCommentsPremiumOrthocell’s easy cell into US as it secures distributors

Orthocell says it has moved at ‘warp speed’ to secure US distributors for its nerve repair device, marking another milestone in its commercialisation push into the world’s biggest healthcare market.

Cheyanne Enciso

Telehealth startup BlinkLab hopes to commercialise a smartphone app to help diagnose autism.

BiotechCommentsPremiumBlinkLab raises $7.7m to bankroll smartphone autism test

WA diagnostics startup BlinkLab has raised nearly $8 million to bankroll a clinical trial for its smartphone autism test ahead of a US Food And Drug Administration submission.

Cheyanne Enciso

Orthocell CEO Paul Anderson.

BiotechCommentsPremiumOrthocell adds Canada to string of approvals for Remplir

Orthocell has added Canada to its string of regulatory approvals for its flagship nerve repair product.

Cheyanne Enciso

Orthocell managing director Paul Anderson.

BiotechCommentsPremiumOrthocell shares soar on latest tick for new market entry

WA biotech Orthocell has received the green light to start selling its nerve repair product into the Thai market, worth $131 million.

Cheyanne Enciso

Orthocell boss Paul Anderson holding its Striate+ product.

BiotechPremiumOrthocell posts strong revenue growth following US approval

WA regenerative medicine company Orthocell has posted a near-40 per cent jump in fourth quarter revenue just days after it won a major regulatory clearance in the US.

Cheyanne Enciso

An unhealthy tariff.

BiotechCommentsTrump’s drug hit hint deals fresh blow to Australia

US President Donald Trump has signalled a tariff on imported pharmaceuticals, a policy that is expected to directly hit Australia’s second-largest export to the US.

Jackson Hewett

PYC Therapeutics chief Rohan Hockings at its facility in Nedlands.

BiotechCommentsPremiumPYC Therapeutics facing $13m hole in $146m equity raising

PYC Therapeutics is facing a $13 million hole as one of its underwriters struggle to fill its share of a shortfall from the biotech’s $146m equity raising.

Cheyanne Enciso

Orthocell boss Paul Anderson at its manufacturing facility in Murdoch.

BiotechCommentsPremiumWA’s Orthocell gets green light for $109m Brazilian market

Orthocell has approval to start selling its dental bone repair product into the $US65 million ($109m) Brazilian market.

Cheyanne Enciso

Spearheading calls for the WA Government to match the existing R&D tax incentive is BlinkLab boss Brian Leedman.

The West Australian exclusive
The West Australian exclusive
BiotechCommentsPremium
The West Australian exclusive
‘Shift the dial’: WA biotechs call for R&D top-up scheme

A group of WA biotechs have urged the State Government to match the existing Federal research and development tax incentive in a move they are certain will attract and retain talent.

Cheyanne Enciso

Orthocell CEO Paul Anderson.

updated
updated
BiotechCommentsPremium
updated
‘No need’: Orthocell won’t move production to avoid tariffs

WA biotech Orthocell says there’s no need to shift production to the US to dodge Donald Trump’s tariffs as it wins clearance from the Food and Drug Administration to start selling its nerve repair product.

Cheyanne Enciso